Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

Cellectis

Status and phase

Terminated

Phase 1

Conditions

Relapsed/Refractory Multiple Myeloma

Treatments

Biological: UCARTCS1A

Study type

Interventional

Funder types

Industry

Identifiers

NCT04142619

UCARTCS1A_01

Details and patient eligibility

About

This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).

Enrollment

11 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with confirmed diagnosis of active multiple myeloma (as defined by International Myeloma Working Group [IMWG] criteria) who have relapsed/refractory disease after and have received at least 3 prior lines of prior therapy.
Eastern Cooperative Oncology Group Performance Status of 0 or 1;
No previous treatment with investigational gene targeting CS1 or chimeric antigen receptor therapy targeting CS1
Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within the screening period.
Other criteria may apply.

Exclusion criteria

Previous treatment with investigational gene therapy targeting CS1 or chimeric antigen receptor therapy targeting CS1;
Any cellular therapy (other than autologous or allogenic HSCT) within 60 days prior to enrollment;
Prior treatment with rituximab or other anti-CD20 therapy within 3 months
Any known active or uncontrolled infection
Autologous hematopoietic stem cell transplantation (HSCT) within 12 weeks prior to enrollment; any cellular therapy (other than autologous) within 60 days prior to enrollment; prior allogeneic HSCT.
Seropositive for Hepatitis C virus or positive for Hepatitis B surface antigen or core antibody.
Presence of active and clinically relevant central nervous system disorder, such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, or organic brain syndrome.